CD8A and neoplasm: For example, the systemic delivery of miR-34a mimics encapsulated in lipid nanoparticles downregulates PD-L1 and oncogenic targets such as BCL2 and MET in triple-negative breast cancer, leading to enhanced CD8+ T-cell infiltration and a 70% greater tumor reduction when combined with anti-PD-1 therapy compared to monotherapy in murine models [122].